COMMUNIQUÉS West-GlobeNewswire

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
31/07/2025
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue [...]
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
31/07/2025
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needs Inflammatory [...]
Little Leaves Behavioral Services Opens Two New Locations in Maryland
31/07/2025
ABA therapy centers in Middle River and Owings Mills expand access to high-quality, early intervention services for young children with autism SILVER SPRING, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Little Leaves [...]
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
31/07/2025
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision [...]
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
31/07/2025
Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has recommended to continue [...]
The Global Biologics Outsourcing Market Accounted for $20.7B in 2024 Driven by Rising Demand for Modality-Specific, End-to-End CDMO Capabilities, Finds Alira Health
31/07/2025
Annual, signature publication provides updated analysis of global CDMO trends, market shifts, and the accelerating impact of advanced therapies FRAMINGHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global [...]
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
31/07/2025
OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its [...]
Elucent Medical Marks 25,000 Lives Impacted Through EnVisio® Technology
31/07/2025
MINNEAPOLIS, July 31, 2025 (GLOBE NEWSWIRE) -- Elucent Medical is proud to announce that more than 25,000 successful procedures have been performed using the EnVisio® In-Body Spatial Intelligence™ platform. This [...]
CoRegen, Inc. Appoints Biotech Veteran Sonal Gupta, M.D., Ph.D., as Chief Medical Officer
31/07/2025
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- CoRegen , a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced the appointment of [...]
ADR Ratio Change Effective
31/07/2025
July 31, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company [...]
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
31/07/2025
New Results Reveal Unprecedented Inhibition Rates and First Evidence of SIL204's Efficacy Against Previously Untested KRAS Q61H Mutation in Human Cancer Cells, Significantly Expanding its Pan-KRAS Potential; Company on [...]
Accelerating Alzheimer’s Research: Groundbreaking Alzheimer's Disease Dataset Now Available to the Public
31/07/2025
Data from Most Deeply Characterized Cohort Across Alzheimer's Disease Released by Global Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative WASHINGTON, July 31, 2025 (GLOBE NEWSWIRE) -- The Global [...]
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance
31/07/2025
COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 [...]
Integra LifeSciences Reports Second Quarter 2025 Financial Results
31/07/2025
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending [...]
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
31/07/2025
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities [...]
SAFE - Informations complémentaires concernant le report de publication des résultats annuels 2024
31/07/2025
Informations complémentaires concernant le report de publication des résultats annuels 2024 Fleurieux-sur-l’Arbresle – France – 31 juillet 2025 à 12h - Safe (FR001400RKU0 – ALSAF) annonce qu’elle devrait disposer de l’ [...]
ICPO and SBMN deepen their collaboration to advance Clinical Theranostics Centers of Excellence in Brazil
31/07/2025
ICPO accreditation following international theranostics guidelines and ICPO Academy for Theranostics will fuel the partnership right from start. July 31, 2025 – Wiesbaden, Germany, and Sao Paulo, Brazil. During the [...]
Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook
31/07/2025
WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue [...]
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
31/07/2025
$12.5 million in second quarter PYRUKYND ® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia under active review, [...]

Pages